Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-Label Study of ALN-TTRSC in Transthyretin Cardiac Amyloidosis
2013-002856-33Phase 2Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Sep 2013
- Modality
- Gene Therapies, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of revusiran in amyloidotic transthyretin cardiomyopathy (ATTR-CM) and hereditary transthyretin amyloidosis (hATTR), sponsored by Alnylam Pharmaceuticals. Primary endpoint: Safety and tolerability of multiple doses of ALN-TTRSC. Started Sep 2013; status: completed.
02
Drugs
revusiran
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)hereditary transthyretin amyloidosis (hATTR)
Beyond the preview
Go deeper on 2013-002856-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002856-33.